{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:53:48Z","timestamp":1790254428196,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T00:00:00Z","timestamp":1555113600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["17\/141\/10"],"award-info":[{"award-number":["17\/141\/10"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40273-019-00799-0","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T03:03:32Z","timestamp":1555124612000},"page":"1209-1217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25\u00a0Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3689","authenticated-orcid":false,"given":"Matthew","family":"Walton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,13]]},"reference":[{"key":"799_CR1","unstructured":"National Institute for Health and Care Excellence. Guide to the processes of technology appraisal. 2018. \n                    https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/technology-appraisal-processes-guide-apr-2018.pdf\n                    \n                  . Accessed 1 Jan 2019."},{"key":"799_CR2","unstructured":"Walton M, Sharif S, Hodgson R, Claxton L, Wright K, Simmonds M. Tisagenlecleucel-T for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25\u00a0years: University of York. 2018. \n                    https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2021579\n                    \n                  . Accessed 17 Jan 2019."},{"key":"799_CR3","unstructured":"National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25\u00a0years: technology appraisal guidance [TA554]. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/ta554\/\n                    \n                  . Accessed 17 Jan 2019."},{"key":"799_CR4","unstructured":"Children with Cancer UK. Acute lymphoblastic leukaemia in children. \n                    https:\/\/www.childrenwithcancer.org.uk\/childhood-cancer-info\/cancer-types\/acute-lymphoblastic-leukaemia\/\n                    \n                  . Accessed 16 May 2018."},{"key":"799_CR5","unstructured":"Leukaemia Foundation. What is acute lymphoblastic leukaemia? \n                    https:\/\/www.leukaemia.org.au\/disease-information\/leukaemias\/acute-lymphoblastic-leukaemia\/\n                    \n                  . Accessed 16 May 2018."},{"key":"799_CR6","unstructured":"Cancer Research UK. About acute lymphoblastic leukaemia (ALL). \n                    http:\/\/www.cancerresearchuk.org\/about-cancer\/acute-lymphoblastic-leukaemia-all\/about\n                    \n                  . Accessed 16 May 2018."},{"key":"799_CR7","unstructured":"National Institute for Health and Care Excellence. Cancer Drugs Fund Managed Access Agreement: tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25\u00a0years [ID1167]. 2018. \n                    https:\/\/www.nice.org.uk\/guidance\/ta554\/documents\/final-appraisal-determination-document-2\n                    \n                  . Accessed 17 Jan 2019."},{"key":"799_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pcl.2014.09.006","volume":"62","author":"SL Cooper","year":"2015","unstructured":"Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin N Am. 2015;62:61\u201373.","journal-title":"Pediatr Clin N Am"},{"key":"799_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjh.15208","volume":"181","author":"RS Sellar","year":"2018","unstructured":"Sellar RS, Rowntree C, Vora AJ, Furness CL, Goulden N, Mitchell C, et al. Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003. Br J Haematol. 2018;181:515\u201322.","journal-title":"Br J Haematol"},{"key":"799_CR10","unstructured":"Macmillan Cancer Support. Hyper-CVAD chemotherapy. \n                    https:\/\/www.macmillan.org.uk\/cancerinformation\/cancertreatment\/treatmenttypes\/chemotherapy\/combinationregimen\/hyper-cvad.aspx\n                    \n                  . Accessed 16 May 2018."},{"key":"799_CR11","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1016\/j.bbmt.2010.10.005","volume":"17","author":"MA Pulsipher","year":"2011","unstructured":"Pulsipher MA, Peters C, Pui CH. High risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17:S137\u201348.","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"799_CR12","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130:2317\u201325.","journal-title":"Blood"},{"key":"799_CR13","unstructured":"European Medicines Agency. Kymriah: summary of product characteristics. 2018. \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/kymriah-epar-product-information_en.pdf\n                    \n                  . Accessed 17 Jan 2019."},{"key":"799_CR14","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1182\/blood.V128.22.2801.2801","volume":"128","author":"SL Maude","year":"2016","unstructured":"Maude SL, Pulsipher MA, Boyer MW, Grupp SA, Davies SM, Phillips CL, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed\/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood. 2016;128:2801.","journal-title":"Blood"},{"key":"799_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"799_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/blood-2016-01-693887","volume":"128","author":"SL Maude","year":"2016","unstructured":"Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed\/refractory acute lymphoblastic leukemia. Blood. 2016;128:217.","journal-title":"Blood"},{"key":"799_CR17","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A Stackelberg von","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381\u20139.","journal-title":"J Clin Oncol"},{"key":"799_CR18","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","volume":"24","author":"S Jeha","year":"2006","unstructured":"Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24:1917\u201323.","journal-title":"J Clin Oncol"},{"key":"799_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","volume":"21","author":"R Hettle","year":"2017","unstructured":"Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21:1\u2013204.","journal-title":"Health Technol Assess"},{"key":"799_CR20","first-page":"1330","volume":"130","author":"J Snider","year":"2017","unstructured":"Snider J, Brauer M, Hao Y, Karaca-Mandic P, Gizaw Tebeka M, Zhang J, et al. The economic value of CTL019 therapy for pediatric patients with relapsed and refractory acute lymphoblastic leukemia in the United Kingdom. Blood. 2017;130:1330.","journal-title":"Blood"},{"key":"799_CR21","unstructured":"NHS Improvement. National schedule of reference costs 2016\u201317. London: NHS England. 2017. \n                    https:\/\/improvement.nhs.uk\/resources\/reference-costs\/\n                    \n                  . Accessed 17 Jan 2019."},{"key":"799_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.14965","volume":"180","author":"M Kuhlen","year":"2017","unstructured":"Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, et al. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003\/2007 trial. Br J Haematol. 2017;180:82\u20139.","journal-title":"Br J Haematol"},{"key":"799_CR23","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","volume":"32","author":"W Sun","year":"2018","unstructured":"Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32:2316.","journal-title":"Leukemia"},{"key":"799_CR24","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836\u201347. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609783\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"799_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/pbc.25451","volume":"62","author":"MJ Kelly","year":"2015","unstructured":"Kelly MJ, Pauker SG, Parsons SK. Using nonrandomised studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:790\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"799_CR26","doi-asserted-by":"publisher","first-page":"e38015","DOI":"10.1371\/journal.pone.0038015","volume":"7","author":"S Essig","year":"2012","unstructured":"Essig S, von der Weid NX, Strippoli MPF, Rebholz CE, Michel G, Rueegg CS, Niggli FK, Kuehni CE. Health-related quality of life in long-term survivors of relapsed childhood acute lymphoblastic leukemia. PLoS ONE. 2012;7:e38015.","journal-title":"PLoS ONE"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00799-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T19:31:16Z","timestamp":1586633476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00799-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,13]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00799-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,13]]},"assertion":[{"value":"13 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme (Project number 17\/141\/10). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the National Institute for Health and Care Excellence or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matthew Walton, Sahar Sharif, Rob Hodgson, Lindsay Claxton, and Mark Simmonds have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}